Tellimer

IN : Dr. Lal Pathlabs Ltd. - Improving margins led by cost control

Recovery in base business patient volumes along with higher tests per patient. COVID-19 related tests and realisations volatile; declined by 50%/35% qoq. Raise revenue/PAT estimates by 1-7% over FY22F-23F; maintain Hold.


Most Viewed See latest
Disclosures

This publication is being distributed by Tellimer solely for information purposes irrespective of a particular user's means, financial situation or investment objectives. The information does not con...

Full Tellimer disclaimers